# A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Patients With Degenerative Mild Cognitive Impairment

> **NCT05041790** · PHASE4 · UNKNOWN · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 418 (estimated)

## Conditions studied

- Mild Cognitive Impairment

## Interventions

- **DRUG:** Choline Alfoscerate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05041790
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-09-30
- **Primary completion:** 2024-11-30
- **Final completion:** 2024-11-30
- **Target enrollment:** 418 (ESTIMATED)
- **Last updated:** 2021-09-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05041790

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05041790, "A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Patients With Degenerative Mild Cognitive Impairment". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05041790. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*